Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Dermatology ; 225(3): 204-9, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23128401

RESUMO

BACKGROUND: Dermatosurgery (DS) is a growing sector in dermatology. Performance measurement is organized worldwide to improve the quality of health care. Clinical audit relies on self-assessment, comparison with guidelines, frames of references and implementation of improvement actions. OBJECTIVE: To assess the efficiency of our DS department. METHODS: A clinical audit focusing on the organization of the DS unit, patient routing, continuing medical education and training for students was conducted by two external auditors. After an initial evaluation, improvements were implemented and reassessed 1 year later by the same auditors. RESULTS: The audit resulted in the implementation of preoperative consultation, improved pre- and postoperative information leaflets for patients, standardizing of surgery reports, earmarking of funds for materials, and patient satisfaction survey. The training of residents was organized. CONCLUSION: This audit was a driving force for communication among the medical and paramedical teams and helped improve patient care and training of residents in DS. It also highlighted areas needing further improvement.


Assuntos
Procedimentos Cirúrgicos Dermatológicos/normas , Dermatologia/normas , Assistência Perioperatória/normas , Garantia da Qualidade dos Cuidados de Saúde/normas , Gestão da Qualidade Total/normas , Comunicação , França , Departamentos Hospitalares/organização & administração , Departamentos Hospitalares/normas , Humanos , Satisfação do Paciente , Médicos , Encaminhamento e Consulta/normas
2.
Ann Dermatol Venereol ; 131(8-9): 769-72, 2004.
Artigo em Francês | MEDLINE | ID: mdl-15505542

RESUMO

BACKGROUND: Few cases of cutaneous lymphocytic hyperplasia secondary to vaccination have been published, although such lesions are not rare. PATIENTS AND METHODS: We report a series of 10 cases registered between 1993 and 2003. RESULTS: Mean age was 25. The clinical aspect was solitary or multiple subcutaneous nodules, located on the arm, developing after a delay of 1 to 18 months after vaccination. Histologic examination showed a lymphocytic infiltration of the subcutaneous fat, with diffuse and/or follicular pattern, without nuclear atypia, the morphological and immunohistochemical analysis of which revealed the benign nature. In all cases, there was fibrosis and granuloma composed of lymphocytes, plasma cells, eosinophils and macrophages with basophilic cytoplasm. Morin stain showed intralesional aluminium in the 6 investigated cases. Evolution was always benign, with no relapse following exeresis. DISCUSSION: Cutaneous lymphocytic hyperplasia secondary to vaccination has to be suspected in a young patient with subcutaneous nodules appearing at a vaccination site. Evidence of aluminium in the lesions supports the diagnosis and the hypothesis that aluminium in the vaccine excipient might have a role in the onset of such lesions.


Assuntos
Alumínio/efeitos adversos , Alumínio/isolamento & purificação , Excipientes/efeitos adversos , Granuloma/etiologia , Vacinação/efeitos adversos , Adolescente , Adulto , Biópsia , Criança , Pré-Escolar , Feminino , Humanos , Hiperplasia , Linfócitos , Masculino , Pessoa de Meia-Idade , Pele/patologia
3.
Ann Dermatol Venereol ; 130(2 Pt 1): 202-4, 2003 Feb.
Artigo em Francês | MEDLINE | ID: mdl-12671585

RESUMO

INTRODUCTION: Interferon alpha has many side effects. Among them the risk of occurrence of seizures is not well known by dermatologists. We report three cases of seizures that occurred in patients treated with interferon alpha in two dermatological diseases: mycosis fungoides and melanoma. OBSERVATIONS: A 68 year-old man, treated for mycosis fungoides, and two men aged 47 and 52 years, treated for melanoma, were under interferon alpha. After 11 months, 3 weeks and 9.5 months, respectively, the three patients had seizures without any past history of epilepsy. Anamnesis and assessment of each patient (brain CT, biological results) suggested the responsibility of interferon alpha. After withdrawal of the treatment, no relapse was observed after 3 months, 6 months and 1 year later, respectively. DISCUSSION: Seizures during treatment with interferon alpha have already been reported. According to the series their prevalence would be of 1 to 4 p. 100. Their pathophysiology is not well known, but apparently interferon alpha lowers the epileptogenic threshold by affecting the central nervous system either directly or through cytokines or neuromediators. The risk of occurrence of seizures must be known by the prescribing physician who must systematically search for past history of epilepsy or risk factors for seizures. This rare but existing side effect raises the problem of information to be supplied to the patient by the prescribing physician.


Assuntos
Antineoplásicos/efeitos adversos , Interferon-alfa/efeitos adversos , Convulsões/induzido quimicamente , Idoso , Antineoplásicos/uso terapêutico , Feminino , Humanos , Interferon-alfa/uso terapêutico , Masculino , Melanoma/tratamento farmacológico , Pessoa de Meia-Idade , Micose Fungoide/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA